Akebia Therapeutics Inc
Company Profile
Business description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Contact
245 First Street
Suite 1400
CambridgeMA02142
USAT: +1 617 871-2098
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
194
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
stocks
Surge in combat drones drives upgrade for ASX share
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,864.90 | 10.20 | 0.12% |
| CAC 40 | 7,897.19 | 61.88 | 0.79% |
| DAX 40 | 25,231.20 | 291.85 | 1.17% |
| Dow JONES (US) | 51,176.96 | 250.40 | 0.49% |
| FTSE 100 | 10,461.95 | 33.68 | 0.32% |
| HKSE | 23,952.28 | 20.01 | -0.08% |
| NASDAQ | 27,190.86 | 319.27 | 1.19% |
| Nikkei 225 | 69,813.44 | 1,503.98 | 2.20% |
| NZX 50 Index | 13,654.66 | 25.83 | -0.19% |
| S&P 500 | 7,722.72 | 56.27 | 0.73% |
| S&P/ASX 200 | 8,692.00 | 9.90 | 0.11% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |